Ran Tao1,2, Chengzhang Wang1,2, Yin Lu3, Changwei Zhang1, Hao Zhou1,2, Hongxia Chen1, WenJun Li1. 1. Institute of Chemical Industry of Forest Products, CAF, Nanjing, Jiangsu Province 210042, People's Republic of China. 2. Research Institute of Forestry New Technology, CAF, Beijing 100091, People's Republic of China. 3. General Hospital of Eastern Theater Command, Nanjing, Jiangsu Province 210002, People's Republic of China.
Abstract
BACKGROUND: This study demonstrated an innovative formulation including the polyprenol (GBP) lipid and vitamin E-TPGS hybrid nanoparticles (NPs) which was aimed to control the transfer of betulinic acid (BA) and low-substituted hydroxyl fullerenol (C60(OH)n). Additionally, it developed BA-C60(OH)n-GBP-TPGS-NPs delivery system and researched the anti-hepatocellular carcinoma (HCC) effects. MATERIALS AND METHODS: The NPs were prepared by nanoprecipitation with ultrasonic-assisted emulsification (UAE) method. It was characterized by scanning electronic microscopy (SEM), transmission electron microscopy (TEM), FTIR spectrum, size distribution and zeta potential. Physical and chemical properties were evaluated through measurement of drug release, stability studies, drug loading efficiency (DE) and encapsulation efficiency (EE). Biological activities were evaluated through measurement of MTT assay, lactate dehydrogenase leakage assay (LDH), cell proliferation assays, cell apoptosis analysis, comet assay, wound healing assay, cell invasion and Western blot analysis. RESULTS AND CONCLUSIONS: The NPs exhibited clear distribution characteristics, improved solubility and stability. BA and C60(OH)n for the NPs displayed a biphasic release pattern with sustained drug release properties. The mixture of C60(OH)n with different hydroxyl groups may have a certain effect on the stability of the NPs system itself. The NPs could effectively inhibit MHCC97H cell proliferation, migration and invasion in vitro. Combined use of C60(OH)n and BA in GBP lipids may improve the inhibit effect of C60(OH)n or BA against HCC cells and reduce cytotoxicity and genotoxicity of C60(OH)n for normal cells. We concluded that one of the important mechanisms of BA-C60(OH)n-GBP-TPGS-NPs inhibiting MHCC97H cells is achieved by up-regulating the expression of Caspase-3, Caspase-8 and Caspase-9.
BACKGROUND: This study demonstrated an innovative formulation including the polyprenol (GBP) lipid and vitamin E-TPGS hybrid nanoparticles (NPs) which was aimed to control the transfer of betulinic acid (BA) and low-substituted hydroxyl fullerenol (C60(OH)n). Additionally, it developed BA-C60(OH)n-GBP-TPGS-NPs delivery system and researched the anti-hepatocellular carcinoma (HCC) effects. MATERIALS AND METHODS: The NPs were prepared by nanoprecipitation with ultrasonic-assisted emulsification (UAE) method. It was characterized by scanning electronic microscopy (SEM), transmission electron microscopy (TEM), FTIR spectrum, size distribution and zeta potential. Physical and chemical properties were evaluated through measurement of drug release, stability studies, drug loading efficiency (DE) and encapsulation efficiency (EE). Biological activities were evaluated through measurement of MTT assay, lactate dehydrogenase leakage assay (LDH), cell proliferation assays, cell apoptosis analysis, comet assay, wound healing assay, cell invasion and Western blot analysis. RESULTS AND CONCLUSIONS: The NPs exhibited clear distribution characteristics, improved solubility and stability. BA and C60(OH)n for the NPs displayed a biphasic release pattern with sustained drug release properties. The mixture of C60(OH)n with different hydroxyl groups may have a certain effect on the stability of the NPs system itself. The NPs could effectively inhibit MHCC97H cell proliferation, migration and invasion in vitro. Combined use of C60(OH)n and BA in GBP lipids may improve the inhibit effect of C60(OH)n or BA against HCC cells and reduce cytotoxicity and genotoxicity of C60(OH)n for normal cells. We concluded that one of the important mechanisms of BA-C60(OH)n-GBP-TPGS-NPs inhibiting MHCC97H cells is achieved by up-regulating the expression of Caspase-3, Caspase-8 and Caspase-9.
Authors: Massimiliano di Cagno; Paul C Stein; Jakub Styskala; Jan Hlaváč; Natasa Skalko-Basnet; Annette Bauer-Brandl Journal: Eur J Pharm Biopharm Date: 2011-11-28 Impact factor: 5.571
Authors: Koert N J Burger; Rutger W H M Staffhorst; Hanke C de Vijlder; Maria J Velinova; Paul H Bomans; Peter M Frederik; Ben de Kruijff Journal: Nat Med Date: 2002-01 Impact factor: 53.440
Authors: Patrycja Nowak-Sliwinska; Judy R van Beijnum; Angela Casini; Alexey A Nazarov; Georges Wagnieres; Hubert van den Bergh; Paul J Dyson; Arjan W Griffioen Journal: J Med Chem Date: 2011-05-16 Impact factor: 7.446
Authors: T Tengchaisri; R Chawengkirttikul; N Rachaphaew; V Reutrakul; R Sangsuwan; S Sirisinha Journal: Cancer Lett Date: 1998-11-27 Impact factor: 8.679
Authors: Huan Meng; Min Xue; Tian Xia; Zhaoxia Ji; Derrick Y Tarn; Jeffrey I Zink; Andre E Nel Journal: ACS Nano Date: 2011-04-27 Impact factor: 15.881